ObjectiveTo compare the results of controlled- release glipizide and immediate-re- lease glipizide in treating type 2 diabetes mellitus.Methods22 patients took controlled-release glipi- zide as treating group, 20 took immediate-release glipizide as compared. The glucose tolerance, insulin, C- peptide and HbA1c were measured before and after treatment. ResultsBoth of controlled-release glipizide and immediate-release glipizide had good results for controlling blood sugar, but controlled-re- lease glipizide did not increase insulin and C-peptide level. Conclusion The controlled-release glipizide had safe and reliable results for controlling blood sugar and decreasing insulin resistence.

Objective To investigate the effects of montelukast on atherescleresis and monocyte chemoattractant protein-1 expression in a hyperchulesterolemic rabbit modeL Methods Thirty four male New Zealand white rabbits were randomized into four groups including normal control group (n=6), placebo in normal control group were fed a high cholesterol diet for 12 weeks. Serum lipids were measured at 0, 8 and 12 weeks after intervention. The intima/media ratio, percentages of macrophages or smooth muscle cells in intima and the expression of MCP-1 mRNA were examined. Results Atheresclerosis was evidenced in placebo group and atorvastatin or montelukast treatment significantly reduced neointima (0.32±0.12 and 0.34±0.10 vs. 1.12±0.36,P<0.05) and macrophage content [(9.8±4.6) % and(11.2±3.7) % vs. (34.6±8.8)%,P<0.05], increased SMC content [(18.6±6.9)% and(19.2±8.6)% vs. (5.2±2.3) %, P<0.05] and inhibited expression of MCP-1 mRNA (0.42±0.08 and 0.40±0.06 vs. 2.36±0.48 ,P<0.01). Montelukast had similar anti-atherogenetic effects as atorvastatin but had no influence on plasma lipids. Conclusions Montelukast could attenuate atherosclerosis in this hyperchulesterolemic rabbit model which might be attributed to its anti-inflammatory effects.